Overview

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Study ITI-007-020 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone as treatment for adolescent patients with schizophrenia or schizoaffective disorder.
Phase:
Phase 1
Details
Lead Sponsor:
Intra-Cellular Therapies, Inc.